or ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease. The FDA has agreed in a Type B interaction that data from the ongoing Phase 1/2 STAAR study can serve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback